Analytical Data
-
Gene name
CD276
- Application
-
Alternative Names
B7-H3; B7H3; CD276 Molecule; B7 homolog 3; Costimulatory molecule
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5ZPR3
-
Expression Region
Thr47~Ser219
-
Molecular Weight
22kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD276, also known as B7-H3, is a member of the B7 family of immune checkpoint molecules that plays a critical role in modulating immune responses. Initially identified as a glycoprotein expressed on the surface of various immune and non-immune cells, CD276 has garnered significant attention due to its involvement in tumor immune evasion, making it a potential target for cancer immunotherapy. Elevated levels of CD276 are associated with poor prognosis in several malignancies, including melanoma, lung cancer, and prostate cancer, as it promotes T-cell suppression and inhibits anti-tumor immunity. The development of recombinant CD276 protein has facilitated research into its structure, function, and interactions with other immune checkpoints. This protein serves as a valuable tool for elucidating the mechanisms by which CD276 influences immune responses, and for evaluating its potential as a therapeutic target. Furthermore, recombinant CD276 is being investigated for its capacity to generate monoclonal antibodies and other therapeutic agents aimed at enhancing anti-tumor immunity. Understanding the role of CD276 in the immune microenvironment and its functional implications could pave the way for novel immunotherapeutic approaches in oncology.
